DnB Asset Management AS Buys 74,457 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

DnB Asset Management AS grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 116.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,665 shares of the company’s stock after purchasing an additional 74,457 shares during the quarter. DnB Asset Management AS owned about 0.06% of Hims & Hers Health worth $3,353,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its position in shares of Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after buying an additional 218,566 shares during the period. Rockefeller Capital Management L.P. boosted its position in Hims & Hers Health by 5.8% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company’s stock valued at $622,000 after acquiring an additional 1,864 shares in the last quarter. Centiva Capital LP grew its holdings in shares of Hims & Hers Health by 13.1% during the 3rd quarter. Centiva Capital LP now owns 81,811 shares of the company’s stock worth $1,507,000 after acquiring an additional 9,468 shares during the period. HighTower Advisors LLC bought a new position in shares of Hims & Hers Health in the 3rd quarter worth approximately $207,000. Finally, Quarry LP lifted its stake in shares of Hims & Hers Health by 91.0% in the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after purchasing an additional 2,913 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HIMS has been the topic of several recent research reports. Leerink Partners upped their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Bank of America upped their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research report on Tuesday, March 18th. Piper Sandler lifted their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. Needham & Company LLC upped their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $37.31.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total value of $174,724.13. Following the completion of the transaction, the insider now owns 193,601 shares of the company’s stock, valued at $4,659,976.07. This represents a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 268,932 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,061,718 shares of company stock valued at $37,894,395. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Up 2.0 %

NYSE HIMS opened at $29.73 on Tuesday. The firm has a market capitalization of $6.60 billion, a P/E ratio of 67.56 and a beta of 1.37. The company has a 50-day moving average price of $39.92 and a 200-day moving average price of $29.67. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.